Loading...
Loading...
VYGR| Name | Value |
|---|---|
| Revenues | 90.1M |
| Cost of Revenue | 1.3M |
| Gross Profit | 88.7M |
| Operating Expense | 34.7M |
| Operating I/L | 54.1M |
| Other Income/Expense | 3.2M |
| Interest Income | 3.2M |
| Pretax | 57.2M |
| Income Tax Expense | 0.8M |
| Net Income/Loss | 56.4M |
Voyager Therapeutics, Inc. is a gene therapy company specializing in the development of treatments and next-generation platform technologies. The company's primary focus is on its lead clinical candidate, VY-AADC, currently in an open-label Phase 1 clinical trial for Parkinson's disease treatment. Additionally, Voyager Therapeutics has preclinical programs targeting amyotrophic lateral sclerosis, Huntington's disease, Friedreich's ataxia, and tauopathies, including Alzheimer's disease. The company generates revenue through collaboration and license agreements with industry leaders such as Neurocrine Biosciences, Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products.
